Enveric Biosciences Inc (ENVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has a cash flow conversion efficiency ratio of -0.600x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($3.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enveric Biosciences Inc - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how Enveric Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Enveric Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.
Enveric Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enveric Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
-1.315x |
|
Baillie Gifford China Growth Trust PLC
LSE:BGCG
|
-0.002x |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.078x |
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
-0.100x |
|
Fonix Mobile plc
LSE:FNX
|
0.339x |
|
Careteq Ltd
AU:CTQ
|
-0.265x |
|
Fastator AB
ST:FASTAT
|
0.082x |
|
Aker Carbon Capture ASA
OL:ACC
|
-0.772x |
Annual Cash Flow Conversion Efficiency for Enveric Biosciences Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of Enveric Biosciences Inc from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see Enveric Biosciences Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.59 Million | $-7.73 Million | -4.851x | +32.67% |
| 2023-12-31 | $1.96 Million | $-14.09 Million | -7.204x | -553.65% |
| 2022-12-31 | $15.56 Million | $-17.15 Million | -1.102x | -114.58% |
| 2021-12-31 | $22.31 Million | $-11.46 Million | -0.514x | +54.88% |
| 2020-12-31 | $3.42 Million | $-3.89 Million | -1.139x | -1766.59% |
| 2019-12-31 | $10.62 Million | $-647.86K | -0.061x | +74.42% |
| 2018-12-31 | $10.76 Million | $-2.57 Million | -0.238x | -69.20% |
| 2017-12-31 | $19.45 Million | $-2.74 Million | -0.141x | +39.21% |
| 2016-12-31 | $11.66 Million | $-2.70 Million | -0.232x | +98.37% |
| 2015-12-31 | $258.53K | $-3.67 Million | -14.202x | -227.36% |
| 2014-12-31 | $-3.87K | $-43.16K | 11.151x | +942.64% |
| 2013-12-31 | $-20.23K | $-21.63K | 1.069x | -13.64% |
| 2012-12-31 | $-20.07K | $-24.85K | 1.238x | +118.59% |
| 2011-12-31 | $4.55K | $-30.35K | -6.662x | -911.20% |
| 2010-12-31 | $-49.52K | $-40.67K | 0.821x | -87.28% |
| 2009-12-31 | $-10.07K | $-65.04K | 6.456x | +308.34% |
| 2008-12-31 | $48.47K | $-150.19K | -3.099x | -1562.39% |
| 2007-12-31 | $1.56 Million | $329.93K | 0.212x | +126.08% |
| 2006-12-31 | $376.50K | $-305.91K | -0.812x | -127.19% |
| 2005-12-31 | $717.40K | $-256.57K | -0.358x | -182.95% |
| 2004-12-31 | $797.74K | $343.94K | 0.431x | +262.19% |
| 2003-12-31 | $955.38K | $-253.97K | -0.266x | -546.12% |
| 2002-12-31 | $1.43 Million | $85.14K | 0.060x | +124.76% |
| 2001-12-31 | $1.41 Million | $-339.68K | -0.241x | -372.35% |
| 2000-12-31 | $1.65 Million | $145.84K | 0.088x | +110.20% |
| 1999-12-31 | $768.14K | $-665.38K | -0.866x | -144.90% |
| 1998-12-31 | $-1.55 Million | $-3.00 Million | 1.929x | +179.57% |
| 1997-12-31 | $1.53 Million | $-3.70 Million | -2.424x | -67.69% |
| 1996-12-31 | $3.27 Million | $-4.72 Million | -1.446x | -48.59% |
| 1995-12-31 | $3.70 Million | $-3.60 Million | -0.973x | -70.27% |
| 1994-12-31 | $1.40 Million | $-800.00K | -0.571x | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more